Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Change in Working Capital
Armata Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Armata Pharmaceuticals Inc
AMEX:ARMP
|
Change in Working Capital
-$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$5.6B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-36%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$1.5B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$912.6m
|
CAGR 3-Years
-81%
|
CAGR 5-Years
-103%
|
CAGR 10-Years
-19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$929.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-20%
|
|
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
See Also
What is Armata Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-1.6m
USD
Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Change in Working Capital amounts to -1.6m USD.
What is Armata Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
14%
Over the last year, the Change in Working Capital growth was 60%.
You don't have any saved screeners yet